Liebson Philip R
Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois.
Clin Cardiol. 2015 May;38(5):309-16. doi: 10.1002/clc.22381. Epub 2015 May 8.
Advances in the novel approach to control ischemic heart disease and heart failure using stem cells or progenitor cells from bone marrow, mesenchyme, or myocardial tissue itself have demonstrated efficacy for increasing left ventricular function, decreasing infarct scar tissue, improving exercise tolerance and heart failure symptoms, and, in some studies, decreasing mortality and reducing rehospitalization for intractable angina or subsequent myocardial infarction. The most common techniques utilize injections of cells into the coronary vasculature or directly into specific areas of vulnerable myocardium. Although few adverse effects have been noted in clinical trials of these procedures, further clinical trials over the next decade should provide further advances in interventional techniques, ancillary supporting technologies to enhance cell regeneration, and applications in ischemic heart disease, cardiomyopathies, and cardiac genetic disorders.
利用来自骨髓、间充质或心肌组织本身的干细胞或祖细胞来控制缺血性心脏病和心力衰竭的新方法取得了进展,已证明其在增强左心室功能、减少梗死瘢痕组织、改善运动耐量和心力衰竭症状方面具有疗效,并且在一些研究中,还能降低死亡率以及减少因顽固性心绞痛或后续心肌梗死而再次住院的情况。最常见的技术是将细胞注射到冠状血管系统或直接注射到易损心肌的特定区域。尽管在这些手术的临床试验中几乎未发现不良反应,但未来十年的进一步临床试验应会在介入技术、增强细胞再生的辅助支持技术以及在缺血性心脏病、心肌病和心脏遗传疾病中的应用方面取得进一步进展。